Costs in inflammatory bowel diseases

Paweł W. Petryszyn; Izabela Witczak

doi:10.5114/pg.2016.57883

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

1/2016
vol. 11

Send email

Copy url:

abstract:

Review paper

Costs in inflammatory bowel diseases

Paweł W. Petryszyn

,

Izabela Witczak

Prz Gastroenterol 2016; 11 (1): 6–13

DOI: https://doi.org/10.5114/pg.2016.57883

Online publish date: 2016/02/11

View full text Get citation

PlumX metrics:

Variables influencing total direct medical costs in inflammatory bowel diseases include country, diagnosis (generally, patients with Crohn’s disease generated higher costs compared with patients with ulcerative colitis), and year since diagnosis. In all studies the mean costs were higher than the median costs, which indicates that a relatively small group of the most severely ill patients significantly affect the total cost of treatment of these diseases. A major component of direct medical costs was attributed to hospitalisation, ranging from 49% to 80% of the total. The costs of surgery constituted 40–61% of inpatient costs. Indirect costs in inflammatory bowel diseases, unappreciated and often underestimated (considered by few authors and as a loss of work), are in fact important and may even exceed direct medical costs.

keywords:

Costs in inflammatory bowel diseases

Paweł W. Petryszyn , Izabela Witczak

inflammatory bowel disease, medical economics

Paweł W. Petryszyn

,

Izabela Witczak